Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to halt the frequent progression of DN to kidney disease and, ultimately, kidney failure—a condition associated with severe morbidity / mortality and high costs to patients, payers, and healthcare systems. As a result, key opinion leaders indicate that efficacious therapies for DN are a major unmet need, and they weigh in on the anticipated nephroprotective effects that endothelin receptor antagonists, mineralocorticoid receptor antagonists, and SGLT-2 inhibitor may offer. These therapies represent the first potentially disease-modifying therapies, should they prove efficacious and safe. The increasing prevalence of DN, exacerbated by the dynamics between clinicians seeking to prescribe new, premium-priced therapies and payers seeking to control costs among an already expensive population, will help shape the changing DN market over the next ten years.

Questions answered

  • Will the inclusion of cardiovascular endpoints in the clinical trials for select therapies be a competitive advantage once commercially available?
  • How do KOLs view the different mechanisms of action of the different therapies in early- and late-phase clinical development?
  • What are the greatest remaining unmet needs in DN? Which drugs in development will fulfill these unmet needs?
  • What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Diabetic Nephropathy - Key Findings - November 2019
    • Key Updates
      • December 2019
      • August 2019
      • June 2019
      • March 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Diabetic Nephropathy?
        • What Factors Are Constraining the Market for Diabetic Nephropathy?
      • Drug Class-Specific Trends
        • Sodium-Glucose Co-Transporter 2 Inhibitors
        • Antidiabetics
        • Mineralocorticoid Receptor Antagonists
        • Antihypertensives
    • Etiology and Pathophysiology
      • Disease Overview
      • Pathophysiology
        • Pathophysiology
      • Natural History of Diabetic Nephropathy
        • Natural History
      • Risk Factors
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Diabetic Nephropathy
        • Diagnosed Prevalent Cases of Diabetic Nephropathy
        • Drug-Treated Cases of Diabetic Nephropathy
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Renin-Angiotensin-Aldosterone System Inhibitors
        • Other Antihypertensive Drug Classes
        • SGLT-2 Inhibitors
        • Other Antidiabetics
      • Medical Practice
        • Overview
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Diabetic Nephropathy
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • SGLT-2 Inhibitors
        • Mineralocorticoid Receptor Antagonists
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Diabetic Nephropathy/Diabetic Kidney Disease
      • Key Discontinuations and Failures in Diabetic Nephropathy
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Diabetic Nephropathy Bibliography
    • Forecast

Author(s): Dwaipayan Chatterjee, M.Pharm; Joseph Granato, MPH

Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group. He holds a degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.

Joseph Granato joined Decision Resources Group in 2012 and previously worked on both Market Access and Global Market Access ; Joseph is currently responsible for forecasting the prevalence and incidence of disease populations throughout the ; He is also tasked with identifying at risk populations and developing new epidemiological methods used to predict overall population health. He received his from Des Moines University where he worked on several population health projects including the delivery of continuing medical education on tick-borne ; He also holds a in Animal Science from the University of ; Prior to his time with DRG Joseph worked with the Monroe County Health Department on the surveillance of reportable diseases including Dengue Fever.


Related Reports

Diabetic Nephropathy | Current Treatment | Detailed, Expanded Analysis (US)

Diabetic nephropathy (DN), also known as diabetic kidney disease, refers to kidney function damage caused by diabetes. DN is a leading cause of chronic kidney disease (CKD) and is associated with...

View Details